OXTR and neoplasm: Targeting OTR for breast tumour growth inhibition and tumour reduction was studied in vivo in mouse mammary carcinoma TS/A [96], rat carcinoma D-R3230AC [96] and mouse MC4-L2 carcinoma [56, 97] (Table 1).